Co-Authors
This is a "connection" page, showing publications co-authored by Doris Benbrook and Vishal Chandra.
Connection Strength
2.486
-
Mortalin and PINK1/Parkin-Mediated Mitophagy Represent Ovarian Cancer-Selective Targets for Drug Development. Adv Sci (Weinh). 2025 Jul 20; e05592.
Score: 0.981
-
Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. Cancers (Basel). 2021 May 12; 13(10).
Score: 0.734
-
Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomed Pharmacother. 2023 May; 161:114422.
Score: 0.208
-
Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. Front Oncol. 2022; 12:958536.
Score: 0.202
-
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570.
Score: 0.145
-
Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016 Jan; 27(1):e8.
Score: 0.126
-
Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. AAPS J. 2023 Dec 12; 26(1):5.
Score: 0.055
-
Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. J Pharm Sci. 2018 02; 107(2):638-646.
Score: 0.036